Novartis: Higher Guidance, Now A Buy

jetcityimage Following the Sandoz spin-off and Alcon sale, Novartis (NYSE:NVS) (OTCPK:NVSEF) has completed a big step in its transformation into a pure-play in innovative medicines (Fig 1). Novartis Pure-play Innovative Medicines Fig 1 Post Investor Day, we decided to raise our EPS forecast to CHF 7, arriving at a valuation of CHF 101.5 per share. Here at the Lab, we had mixed feelings about the company. On the one hand, Novartis is a quality business with a solid balance sheet and a strong R&D franchise. D ...